Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06525766 · ClinicalTrials.gov registry record · Phase 2

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

A Phase 2 study of Metastatic Breast Cancer and Anatomic Stage IV Breast Cancer AJCC v8, sponsored by Mayo Clinic.

Recruiting
Registry status
Phase 2
Development phase
35
Enrollment target
1
Study location

NCT06525766 is a Phase 2 study of Metastatic Breast Cancer and Anatomic Stage IV Breast Cancer AJCC v8 that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 35 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06525766, a Phase 2 study of Metastatic Breast Cancer and Anatomic Stage IV Breast Cancer AJCC v8, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
Phase 2
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

This phase II trial evaluates the effect of capecitabine on tumor response using imaging and tumor markers to adjust dose (adaptive therapy) in patients with estrogen receptor (ER) positive, HER2 negative breast cancer that has spread from where it first started to other areas in the body (metastatic). Capecitabine is in a class of medications called antimetabolites. It is taken up by tumor cells and breaks down into fluorouracil, a substance that kills tumor cells. Adaptive therapy with capecitabine based on tumor burden response may slow or stop the growth of tumor cells in patients with metastatic ER positive, HER2 negative breast cancer.

Conditions Studied

Metastatic Breast Cancer Anatomic Stage IV Breast Cancer AJCC v8 Estrogen Receptor-positive Breast Cancer Metastatic HER2-Negative Breast Carcinoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • DRUG Capecitabine
  • PROCEDURE Magnetic Resonance Imaging
  • PROCEDURE Bone Scan

Study Locations (1)

Arizona

  • Mayo Clinic in Arizona - Scottsdale

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2025-10-01
Est. Completion 2030-10-15
Phase Phase 2

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06525766

The ClinicalTrials.gov registry entry for NCT06525766 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (83% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06525766 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT06525766 about?

NCT06525766 is a clinical study titled "Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer". This phase II trial evaluates the effect of capecitabine on tumor response using imaging and tumor markers to adjust dose (adaptive therapy) in patients with estrogen receptor (ER) positive, HER2 negative breast cancer that has spread from where it first started to other areas in the body (metastati...

What is the current status of trial NCT06525766?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2025-10-01. Estimated completion is 2030-10-15.

What conditions does trial NCT06525766 study?

This clinical trial studies the following conditions: Metastatic Breast Cancer, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-positive Breast Cancer, Metastatic HER2-Negative Breast Carcinoma.

What interventions are being tested in trial NCT06525766?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Capecitabine (DRUG), Magnetic Resonance Imaging (PROCEDURE), Bone Scan (PROCEDURE).

Who is sponsoring clinical trial NCT06525766?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06525766 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Breast Cancer

All registered trials for this condition

Anatomic Stage IV Breast Cancer AJCC v8

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.